These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 16368442

  • 1. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.
    Jefferson JW, Pradko JF, Muir KT.
    Clin Ther; 2005 Nov; 27(11):1685-95. PubMed ID: 16368442
    [Abstract] [Full Text] [Related]

  • 2. Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity.
    Kharasch ED, Mitchell D, Coles R.
    J Clin Pharmacol; 2008 Apr; 48(4):464-74. PubMed ID: 18287571
    [Abstract] [Full Text] [Related]

  • 3. Steady-state clinical pharmacokinetics of bupropion extended-release in youths.
    Daviss WB, Perel JM, Birmaher B, Rudolph GR, Melhem I, Axelson DA, Brent DA.
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1503-9. PubMed ID: 17135996
    [Abstract] [Full Text] [Related]

  • 4. Steady-state pharmacokinetics of bupropion SR in juvenile patients.
    Daviss WB, Perel JM, Rudolph GR, Axelson DA, Gilchrist R, Nuss S, Birmaher B, Brent DA.
    J Am Acad Child Adolesc Psychiatry; 2005 Apr; 44(4):349-57. PubMed ID: 15782082
    [Abstract] [Full Text] [Related]

  • 5. Effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion and its active metabolite, 4-hydroxybupropion, in healthy subjects.
    Kim H, Bae SK, Park SJ, Shim EJ, Kim HS, Shon JH, Liu KH, Shin JG.
    Br J Clin Pharmacol; 2010 Jul; 70(1):126-31. PubMed ID: 20642555
    [Abstract] [Full Text] [Related]

  • 6. Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity.
    Loboz KK, Gross AS, Williams KM, Liauw WS, Day RO, Blievernicht JK, Zanger UM, McLachlan AJ.
    Clin Pharmacol Ther; 2006 Jul; 80(1):75-84. PubMed ID: 16815319
    [Abstract] [Full Text] [Related]

  • 7. Serum concentrations of hydroxybupropion for dose optimization of depressed patients treated with bupropion.
    Laib AK, Brünen S, Pfeifer P, Vincent P, Hiemke C.
    Ther Drug Monit; 2014 Aug; 36(4):473-9. PubMed ID: 24452068
    [Abstract] [Full Text] [Related]

  • 8. Acute antidepressant response and plasma levels of bupropion and metabolites in a pediatric-aged sample: an exploratory study.
    Daviss WB, Perel JM, Brent DA, Axelson DA, Rudolph GR, Gilchrist R, Nuss S, Birmaher B.
    Ther Drug Monit; 2006 Apr; 28(2):190-8. PubMed ID: 16628130
    [Abstract] [Full Text] [Related]

  • 9. An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction.
    Reese MJ, Wurm RM, Muir KT, Generaux GT, St John-Williams L, McConn DJ.
    Drug Metab Dispos; 2008 Jul; 36(7):1198-201. PubMed ID: 18420781
    [Abstract] [Full Text] [Related]

  • 10. Population Pharmacokinetics, Safety and Tolerability of Extended-Release Bupropion and Its Three Metabolites in Chinese Healthy Volunteers.
    Zhang F, Li Y, Hu J, Zhong J, Li H.
    Eur J Drug Metab Pharmacokinet; 2019 Jun; 44(3):339-352. PubMed ID: 30520001
    [Abstract] [Full Text] [Related]

  • 11. Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender.
    Stewart JJ, Berkel HJ, Parish RC, Simar MR, Syed A, Bocchini JA, Wilson JT, Manno JE.
    J Clin Pharmacol; 2001 Jul; 41(7):770-8. PubMed ID: 11452710
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation.
    Palovaara S, Pelkonen O, Uusitalo J, Lundgren S, Laine K.
    Clin Pharmacol Ther; 2003 Oct; 74(4):326-33. PubMed ID: 14534519
    [Abstract] [Full Text] [Related]

  • 13. Bupropion sustained release: a therapeutic overview.
    Davidson JR, Connor KM.
    J Clin Psychiatry; 1998 Oct; 59 Suppl 4():25-31. PubMed ID: 9554318
    [Abstract] [Full Text] [Related]

  • 14. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects.
    Robertson SM, Maldarelli F, Natarajan V, Formentini E, Alfaro RM, Penzak SR.
    J Acquir Immune Defic Syndr; 2008 Dec 15; 49(5):513-9. PubMed ID: 18989234
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of bupropion and its metabolites in haemodialysis patients who smoke. A single dose study.
    Worrall SP, Almond MK, Dhillon S.
    Nephron Clin Pract; 2004 Dec 15; 97(3):c83-9. PubMed ID: 15292684
    [Abstract] [Full Text] [Related]

  • 16. Bupropion sustained release: side effect profile.
    Settle EC.
    J Clin Psychiatry; 1998 Dec 15; 59 Suppl 4():32-6. PubMed ID: 9554319
    [Abstract] [Full Text] [Related]

  • 17. Rapid clinical induction of bupropion hydroxylation by metamizole in healthy Chinese men.
    Qin WJ, Zhang W, Liu ZQ, Chen XP, Tan ZR, Hu DL, Wang D, Fan L, Zhou HH.
    Br J Clin Pharmacol; 2012 Dec 15; 74(6):999-1004. PubMed ID: 22519658
    [Abstract] [Full Text] [Related]

  • 18. Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects.
    Hogeland GW, Swindells S, McNabb JC, Kashuba AD, Yee GC, Lindley CM.
    Clin Pharmacol Ther; 2007 Jan 15; 81(1):69-75. PubMed ID: 17186001
    [Abstract] [Full Text] [Related]

  • 19. Persistence with once-daily versus twice-daily bupropion for the treatment of depression in a large managed-care population.
    Stang P, Suppapanaya N, Hogue SL, Park D, Rigney U.
    Am J Ther; 2007 Jan 15; 14(3):241-6. PubMed ID: 17515697
    [Abstract] [Full Text] [Related]

  • 20. Stereoselective Steady-State Disposition and Bioequivalence of Brand and Generic Bupropion in Adults.
    Kharasch ED, Neiner A, Kraus K, Blood J, Stevens A, Miller JP, Lenze EJ.
    Clin Pharmacol Ther; 2020 Nov 15; 108(5):1036-1048. PubMed ID: 32386065
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.